Ocugen (NASDAQ:OCGN) Price Target Raised to $10.00

Ocugen (NASDAQ:OCGN) had its price objective upped by HC Wainwright from $7.00 to $10.00 in a research report released on Wednesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Ocugen’s Q1 2026 earnings at ($0.05) EPS, Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.18) EPS, FY2028 earnings at $0.18 EPS, FY2029 earnings at $0.84 EPS and FY2030 earnings at $1.79 EPS.

Several other research firms have also weighed in on OCGN. Canaccord Genuity Group began coverage on Ocugen in a report on Tuesday, March 17th. They set a “buy” rating and a $12.00 target price on the stock. Wall Street Zen upgraded Ocugen from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Oppenheimer started coverage on Ocugen in a research report on Wednesday, March 11th. They set an “outperform” rating and a $10.00 price target on the stock. Chardan Capital reiterated a “buy” rating and set a $7.00 price objective on shares of Ocugen in a report on Thursday, March 5th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ocugen in a research report on Thursday, January 22nd. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.75.

Ocugen Stock Down 4.6%

Shares of NASDAQ:OCGN opened at $1.87 on Wednesday. The company has a 50 day moving average price of $1.74 and a two-hundred day moving average price of $1.54. The company has a debt-to-equity ratio of 8.04, a quick ratio of 1.06 and a current ratio of 1.06. The company has a market capitalization of $613.17 million, a PE ratio of -8.13 and a beta of 2.75. Ocugen has a 52 week low of $0.57 and a 52 week high of $2.73.

Ocugen (NASDAQ:OCGN) last announced its quarterly earnings results on Wednesday, March 4th. The company reported ($0.06) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.06). Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 2,626.38%. The company had revenue of ($0.19) million for the quarter, compared to analysts’ expectations of $0.86 million. Analysts forecast that Ocugen will post -0.2 earnings per share for the current year.

Institutional Trading of Ocugen

Several hedge funds and other institutional investors have recently modified their holdings of the company. SmartHarvest Portfolios LLC acquired a new position in shares of Ocugen during the fourth quarter worth about $31,000. BNP Paribas Financial Markets grew its holdings in shares of Ocugen by 56.7% during the second quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company’s stock worth $36,000 after buying an additional 13,326 shares in the last quarter. NewEdge Advisors LLC raised its position in Ocugen by 198.0% in the 2nd quarter. NewEdge Advisors LLC now owns 36,814 shares of the company’s stock valued at $36,000 after buying an additional 24,460 shares during the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in Ocugen in the 4th quarter valued at approximately $38,000. Finally, Cora Capital Advisors LLC lifted its stake in Ocugen by 27.5% in the 4th quarter. Cora Capital Advisors LLC now owns 30,143 shares of the company’s stock valued at $41,000 after acquiring an additional 6,500 shares in the last quarter. Institutional investors and hedge funds own 10.27% of the company’s stock.

Trending Headlines about Ocugen

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: HC Wainwright raised several 2026 quarterly EPS forecasts (Q1–Q4 moved toward ($0.05) from ($0.06)), boosted FY2026 and materially raised long‑range revenue/earnings assumptions (FY2028–FY2030), and reiterated a “Buy” rating with a $10 price target — a constructive analyst endorsement that supports longer‑term upside. HC Wainwright Issues Positive Forecast for Ocugen (NASDAQ:OCGN) Stock Price
• Positive Sentiment: Chardan Capital assigned a Buy rating on Ocugen, adding another buy‑side vote that may attract momentum buyers or traders looking for analyst‑driven catalysts. Ocugen (NASDAQ:OCGN) Earns Buy Rating from Chardan Capital
• Neutral Sentiment: Consensus for FY2026 EPS remains negative (around ($0.20) per share), so while some analysts are lifting estimates, the market still expects a loss this year — keeping Ocugen in speculative/biotech territory.
• Negative Sentiment: Noble Financial lowered near‑term EPS estimates (Q3 2026 to ($0.07) and Q4 2026 to ($0.08); FY2026 to ($0.26)), signaling concern about near‑term performance and adding selling pressure from cautious shops.
• Negative Sentiment: Clinical setback: Phase II data for OCU410 in an eye disease trial showed lower lesion reduction versus earlier results (despite a reported 31% improvement), which triggered the immediate stock weakness as investors reassess clinical and regulatory risk. Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.